<VariationArchive VariationID="1066734" VariationName="NC_000002.11:g.(?_189839206)_(189950508_?)del" VariationType="Deletion" Accession="VCV001066734" Version="5" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="1" DateLastUpdated="2024-07-29" DateCreated="2021-05-10" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1054285" VariationID="1066734">
      <GeneList>
        <Gene Symbol="COL3A1" FullName="collagen type III alpha 1 chain" GeneID="1281" HGNC_ID="HGNC:2201" Source="submitted" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>2q32.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="188974373" stop="189012746" display_start="188974373" display_stop="189012746" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NW_025791764.1" start="79333" stop="117706" display_start="79333" display_stop="117706" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="189839098" stop="189877471" display_start="189839098" display_stop="189877471" Strand="+" />
          </Location>
          <OMIM>120180</OMIM>
          <Haploinsufficiency last_evaluated="2017-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=COL3A1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2017-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=COL3A1">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
        <Gene Symbol="COL5A2" FullName="collagen type V alpha 2 chain" GeneID="1290" HGNC_ID="HGNC:2210" Source="submitted" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>2q32.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="189031898" stop="189441111" display_start="189031898" display_stop="189441111" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="189896640" stop="190044604" display_start="189896640" display_stop="190044604" Strand="-" />
          </Location>
          <OMIM>120190</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000002.11:g.(?_189839206)_(189950508_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>2q32.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" innerStart="189839206" innerStop="189950508" display_start="189839206" display_stop="189950508" variantLength="111303" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.11" sequenceAccession="NC_000002" sequenceVersion="11" change="g.(?_189839206)_(189950508_?)del" Assembly="GRCh37">
            <Expression>NC_000002.11:g.(?_189839206)_(189950508_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000002.11:g.(?_189839206)_(189950508_?)del AND Ehlers-Danlos syndrome, type 4" Accession="RCV001388019" Version="10">
        <ClassifiedConditionList TraitSetID="6334">
          <ClassifiedCondition DB="MedGen" ID="C0268338">Ehlers-Danlos syndrome, type 4</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-04-15" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NC_000002.11:g.(?_189839206)_(189950508_?)del AND Ehlers-Danlos syndrome, classic type, 1" Accession="RCV003154027" Version="9">
        <ClassifiedConditionList TraitSetID="56939">
          <ClassifiedCondition DB="MedGen" ID="C0268335">Ehlers-Danlos syndrome, classic type, 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-04-15" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2020-04-15" NumberOfSubmissions="2" NumberOfSubmitters="1" DateCreated="2021-05-10" MostRecentSubmission="2024-06-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">20648054</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22696272</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24922459</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="56939" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="54525" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Ehlers-Danlos syndrome, type 1</ElementValue>
                <XRef ID="Ehlers-Danlos+Syndrome+Classic+Type/2484" DB="Genetic Alliance" />
                <XRef ID="83470009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">EHLERS-DANLOS SYNDROME, GRAVIS TYPE</ElementValue>
                <XRef Type="MIM" ID="130000" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">EHLERS-DANLOS SYNDROME, SEVERE CLASSIC TYPE</ElementValue>
                <XRef Type="MIM" ID="130000" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">EDS I</ElementValue>
                <XRef Type="MIM" ID="130000" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Ehlers-Danlos syndrome, classic type, 1</ElementValue>
                <XRef ID="MONDO:0019567" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ehlers-Danlos syndrome, classic type I</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">EDSCL1</ElementValue>
                <XRef Type="MIM" ID="130000" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">cEDS</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">EDS1</ElementValue>
                <XRef Type="MIM" ID="130000" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Classic Ehlers-Danlos syndrome (cEDS) is a connective tissue disorder characterized by skin hyperextensibility, atrophic scarring, and generalized joint hypermobility (GJH). The skin is soft and doughy to the touch, and hyperextensible, extending easily and snapping back after release (unlike lax, redundant skin, as in cutis laxa). The skin is fragile, as manifested by splitting of the dermis following relatively minor trauma, especially over pressure points (knees, elbows) and areas prone to trauma (shins, forehead, chin). Wound healing is poor, and stretching of scars after apparently successful primary wound healing is characteristic. Complications of joint hypermobility, such as dislocations of the shoulder, patella, digits, hip, radius, and clavicle, usually resolve spontaneously or are easily managed by the affected individual. Other features include hypotonia with delayed motor development, fatigue and muscle cramps, and easy bruising. Mitral valve prolapse can occur infrequently, but tends to be of little clinical consequence. Aortic root dilatation has been reported, appears to be more common in young individuals, and rarely progresses.</Attribute>
                <XRef ID="NBK1244" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301422</ID>
                <ID Source="BookShelf">NBK1244</ID>
              </Citation>
              <XRef ID="C0268335" DB="MedGen" />
              <XRef ID="MONDO:0019567" DB="MONDO" />
              <XRef Type="MIM" ID="130000" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="6334" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1585" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Ehlers-Danlos syndrome vascular type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ehlers Danlos syndrome, ecchymotic type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ehlers Danlos syndrome, arterial type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ehlers Danlos syndrome, Sack-Barabas type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Ehlers-Danlos syndrome, type 4</ElementValue>
                <XRef ID="Ehlers-Danlos+Syndrome+Vascular+Type/2491" DB="Genetic Alliance" />
                <XRef ID="17025000" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ehlers-Danlos Syndrome Type IV</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">EDS IV</ElementValue>
                <XRef Type="MIM" ID="130050" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">EDS4</ElementValue>
                <XRef Type="MIM" ID="130050" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2082" />
                <XRef ID="2082" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Vascular Ehlers-Danlos syndrome (vEDS) is characterized by arterial, intestinal, and/or uterine fragility; thin, translucent skin; easy bruising; characteristic facial appearance (thin vermilion of the lips, micrognathia, narrow nose, prominent eyes); and an aged appearance to the extremities, particularly the hands. Vascular dissection or rupture, gastrointestinal perforation, or organ rupture are the presenting signs in most adults with vEDS. Arterial rupture may be preceded by aneurysm, arteriovenous fistulae, or dissection but also may occur spontaneously. The majority (60%) of individuals with vEDS who are diagnosed before age 18 years are identified because of a positive family history. Neonates may present with clubfoot, hip dislocation, limb deficiency, and/or amniotic bands. Approximately half of children tested for vEDS in the absence of a positive family history present with a major complication at an average age of 11 years. Four minor diagnostic features – distal joint hypermobility, easy bruising, thin skin, and clubfeet – are most often present in those children ascertained without a major complication.</Attribute>
                <XRef ID="NBK1494" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301667</ID>
                <ID Source="BookShelf">NBK1494</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGenetest, 2010">
                <ID Source="pmc">2987428</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="Orphanet, 2013">
                <URL>https://www.orpha.net/data/patho/Pro/en/Emergency_Ehlers-DanlosTypeIV-enPro4042.pdf</URL>
                <CitationText>Orphanet Emergency Guidelines: Type IV Ehlers-Danlos Syndrome</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="AHA/ASA, 2014">
                <ID Source="PubMed">25355838</ID>
              </Citation>
              <Citation Type="general" Abbrev="CCS, 2014">
                <ID Source="PubMed">24882528</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESC, 2014">
                <ID Source="PubMed">25173340</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="CSANZ, 2017">
                <ID Source="PubMed">28161018</ID>
              </Citation>
              <XRef ID="286" DB="Orphanet" />
              <XRef ID="C0268338" DB="MedGen" />
              <XRef ID="MONDO:0017314" DB="MONDO" />
              <XRef Type="MIM" ID="130050" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3114466" SubmissionDate="2021-01-07" DateLastUpdated="2021-05-10" DateCreated="2021-05-10">
        <ClinVarSubmissionID localKey="NM_000090.3_2_Deletion (entire coding sequence)|MedGen:C0268338" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001588805" DateUpdated="2021-05-10" DateCreated="2021-05-10" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-04-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">20648054</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24922459</ID>
          </Citation>
          <Comment>A gross deletion of the genomic region encompassing the full coding sequence of the COL3A1 gene has been identified. The boundaries of this event are unknown as the deletion extends beyond the assayed region for this gene and therefore may encompass additional genes. Isolated whole-gene deletions of COL3A1 have not been reported in the literature. However, larger copy number events that include this gene have been reported (PMID: 20648054). Loss-of-function variants in COL3A1 are known to be pathogenic (PMID: 24922459). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="COL3A1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000002.11:g.(?_189839206)_(189950508_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268338" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3100837" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2021-05-10">
        <ClinVarSubmissionID localKey="NM_000393.3_2_Deletion (exons 10-54)|MedGen:C0268335" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001575239" DateUpdated="2024-06-09" DateCreated="2021-05-10" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-04-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">22696272</ID>
          </Citation>
          <Comment>In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Gly645Arg amino acid residue in COL5A2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 22696272, Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. This variant has not been reported in the literature in individuals with COL5A2-related conditions. This variant is a gross deletion of the genomic region encompassing exon(s) 10-54 of the COL5A2 gene. The 5' boundary is likely confined to intron 9. The 3' end of this event is unknown as it extends through the termination codon beyond the assayed region for this gene and may encompass additional genes. While this deletion is not anticipated to result in nonsense mediated decay, it is expected to create a truncated protein product or disrupt mRNA translation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="COL5A2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000002.11:g.(?_189839206)_(189950508_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268335" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12974844</SubmissionName>
          <SubmissionName>SUB14505679</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3100837" TraitType="Disease" MappingType="XRef" MappingValue="C0268335" MappingRef="MedGen">
        <MedGen CUI="C0268335" Name="Ehlers-Danlos syndrome, classic type, 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3114466" TraitType="Disease" MappingType="XRef" MappingValue="C0268338" MappingRef="MedGen">
        <MedGen CUI="C0268338" Name="Ehlers-Danlos syndrome, type 4" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

